SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced final results from a randomized, multicenter, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC). MetMAb is a unique one-armed investigational antibody designed to target Met, a protein (or receptor) associated with a poor outcome in many cancers. The study showed that people whose tumors had high levels of Met, as determined by a companion diagnostic, lived twice as long without their disease getting worse (progression-free survival or PFS) when they received MetMAb plus Tarceva® (erlotinib) compared to Tarceva alone.
